University Radiotherapy Center of Antwerp to Install Industry’s First TomoHD(TM) Treatment System

MADISON, WI–(Marketwire – October 27, 2010) –  TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for cancer care, announced today that University Radiotherapy Center of Antwerp, Belgium, has begun installation of the world’s first TomoTherapy^® TomoHD^™ treatment system, a comprehensive radiation therapy system that enables cancer centers to efficiently handle both common and complex tumors with a single device. University Radiotherapy Center Antwerp is a collaboration between the Antwerp University Hospital and the Antwerp Hospital Network (ZNA).

The TomoHD treatment system combines technologies previously only available as options to TomoTherapy’s flagship system, as well as beamline components redesigned for enhanced performance.

Specifically, the TomoHD system includes TomoHelical^™ and TomoDirect^™ delivery modes. The TomoHelical technique enables continuous 360-degree treatment delivery for targeting complex volumes, while TomoDirect offers a discrete-angle delivery option to support highly efficient intensity-modulated radiation therapy (IMRT) and 3D conformal radiation therapy (3D CRT) for more routine cases. In addition, the TomoHD treatment system offers standard 1 cm beam commissioning for enhanced stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) capabilities.

The TomoHD system also includes the Tomo Quality Assurance (TQA™) application, which simplifies collection and analysis of system performance information and provides trending and reporting tools for monitoring machine performance.

“We were interested in adding a TomoTherapy system at our center, but waited for the TomoHD system because we recognize that this integrated solution will enable us to improve the efficiency with which we are able to treat patients with high quality radiation therapy. And the integration of the TomoDirect technique provides us a way to bring the benefits of IG-IMRT to a broader patient base with a single system,” said Prof. Dr. Danielle Van den Weyngaert, head of the department at University Radiotherapy Center. “More importantly, we believe that TomoHD will be the platform we need for supporting future advancements in radiation therapy.”

Patient treatments are expected to commence using the TomoHD treatment system in December. This is the third TomoTherapy system purchased by University Radiotherapy Center. The first two systems were installed in 2007 and have been used to treat patients with advanced image-guided IMRT, and to train TomoTherapy users from institutions across Europe.

With the TomoHD treatment system, University Radiotherapy Center will be able to advance its ability to treat patients with head and neck tumors, particularly those extending into the ocular region, as well as those in the abdominal and lung region where healthy tissue and organs are at risk to radiation exposure. Additionally, the TomoDirect technique will expand the center’s ability to address breast cancer with a fixed angle radiation delivery mode.

“We are pleased to announce that the first TomoHD treatment system installation has begun, less than a year after its commercial introduction to the market,” said TomoTherapy CEO Fred Robertson. “We are honored to work with University Radiotherapy Center of Antwerp to bring this advanced treatment solution to patients in Belgium and beyond.”

The TomoHD treatment system will be on display in the TomoTherapy booth (#3101) at the 52nd annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego, Calif., Oct. 31 – Nov. 4, 2010.

About University Radiotherapy Center of Antwerp
The University Radiotherapy Center Antwerp is a collaboration between the Antwerp University Hospital and the Antwerp Hospital Network (ZNA). Both hospitals offer comprehensive care for patients with complex disorders. Together, the hospitals treat in excess of 300,000 patients every year. The Radiotherapy Center treats patients in two major locations in Antwerp. TomoTherapy^® technology has mainly been used used to treat cancers of the head and neck. The radiotherapy center is also being used as the European TomoTherapy^® training center for physicists and engineers working with the system.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements
Statements in this release regarding future products or product capabilities, events, expectations and other similar matters, including but not limited to statements using the terms “believe,” “may,” “should,” “suggests” or “expects” constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors such as our ability to integrate acquired assets, ability to protect intellectual property, risks of interruption due to events beyond the company’s control, and the other risks listed from time to time in TomoTherapy’s filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy’s judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoHD, Hi·Art, TomoHelical, TomoDirect, TQA, and the TomoTherapy logo are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.